In: The Journal of Infectious Diseases, 2010, vol. 202, no. 7, p. 1076-1087
|
In: Journal of Infectious Diseases, 1996, vol. 174, no. 2, p. 367-372
|
In: Sozial- und Präventivmedizin, 1998, vol. 43, no. 1, p. 18-28
|
In: Sozial- und Präventivmedizin, 1998, vol. 43, no. 1, p. 29-38
|
In: Sozial- und Präventivmedizin, 1998, vol. 43, no. 1, p. 39-48
|
In: Trends in Parasitology, 2015, vol. 31, no. 2, p. 46–51
Currently available drugs for Chagas’ disease are limited by toxicity and low efficacy in the chronic stage. Posaconazole, the most advanced new anti-chagasic drug candidate, did not fully confirm its initial potential in a Phase II clinical trial for chronic Chagas’ disease. Given that posaconazole is highly active against Trypanosoma cruzi in vitro, and was very well tolerated in clinical...
|
In: Open Forum Infectious Diseases, 2015, vol. 3, no. 1, p. -
|
In: Parasitology Research, 2008, vol. 103, no. 3, p. 517-522
|
In: Journal of Antimicrobial Chemotherapy, 2006, vol. 58, no. 6, p. 1193-1197
|
In: Journal of Antimicrobial Chemotherapy, 2006, vol. 57, no. 6, p. 1139-1145
|